Ocrelizumab or Ocrelizumab and Hyaluronidase-ocsq

Covers ocrelizumab (Ocrevus®) and ocrelizumab with hyaluronidase‑ocsq (Ocrevus Zunovo™) as disease‑modifying therapy for adults with relapsing forms of multiple sclerosis and for selected primary progressive MS patients who meet the trial‑based entry criteria. Coverage requires dosing and duration consistent with FDA labeling or authoritative compendia, negative active hepatitis B prior to initiation, no concurrent MS DMTs, completion of live vaccines ≥4 weeks before therapy, and is limited to FDA‑approved or compendia‑/peer‑review‑supported indications (unsupported off‑label uses are excluded).

"Therapy is covered when it is proven effective for the relevant diagnosis or procedure based on generally accepted standards of practice."

Sign up to see full coverage criteria, indications, and limitations.